@Robert can this be refreshed with the most recent Vestrum data cut? We should have considerably more followup

@Robert could we expand from 1) first 6 months and 2) latter 6 months to 1) months 1-6, 2) months 6-12, 3) months 13-18, and 4) months 19-24? With the additional data from more recent Vestrum deliverables, we ought to have sufficient followup for two years of Vabysmo utilization

@Robert could an additional row be added for % of Patient Injections 6 to 12 months?

Confirming this is mean injections?

Can you also provide mean injections in first 6 months and latter 6 months?

is this laterality status? So 4/21 eyes for DME treatment naive were unilateral/treated in only 1 eye, and 17/21 were bilateral/treated in 2 eyes?

I'd expect the a more even split of unilateral/bilateral eyes in the DME than the AMD cohort, can you confirm these flags?

Could you add table 2.x tables by line of business (commercial, medicare, etc.)?

Is this mean follow up injections of eylea?

Is this mean follow up injections of vabysmo?

Is there any more recent data we can run this against? Don't we have data through Aug or Sep 2023?

Is there any more recent data we can run this against? Don't we have data through Aug or Sep 2023?